参考文献/References:
[1] Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis[J]. Endocr Rev,2013,34(3):309-338.
[2] Stocco C. Tissue physiology and pathology of aromatase[J]. Steroids,2012,77(1-2):27-35.
[3] Verma N, Jain V, Birla S, et al. Growth and hormonal profile from birth to adolescence of a girl with aromatase deficiency[J]. J Pediatr Endocrinol Metab,2012,25(11-12):1185-1190.
[4] Gagliardi L, Scott HS, Feng J, et al. A case of Aromatase deficiency due to a novel CYP19A1 mutation[J]. BMC Endocr Disord,2014,14:16.
[5] Marino R, Perez Garrido N, Costanzo M, et al. Five new cases of 46, XX aromatase deficiency:clinical follow-up from birth to puberty, a novel mutation, and a founder effect[J]. J Clin Endocrinol Metab,2015,100(2):E301-E307.
[6] Xi B, Cheng H, Shen Y, et al. Physical activity modifies the associations between genetic variants and hypertension in the Chinese children[J]. Atherosclerosis,2012,225(2):376-380.
[7] Tanira MO, Al Balushi KA. Genetic variations related to hypertension:a review[J]. J Hum Hypertens,2005,19(1):7-19.
[8] de Nicola AF, Brocca ME, Pietranera L, et al. Neuroprotection and sex steroid hormones:evidence of estradiol-mediated protection in hypertensive encephalopathy[J]. Mini Rev Med Chem,2012,12(11):1081-1089.
[9] Shimodaira M, Nakayama T, Sato N, et al. Association study of aromatase gene(CYP19A1)in essential hypertension[J]. Int J Med Sci,2008,5(1):29-35.
[10] Ziv-Gal A, Gallicchio L, Miller SR, et al. A genetic polymorphism in the CYP19A1 gene and the risk of hypertension among midlife women[J]. Maturitas,2012,71(1):70-75.
[11] Shimodaira M, Nakayama T, Sato I, et al. Estrogen synthesis genes CYP19A1, HSD3B1, and HSD3B2 in hypertensive disorders of pregnancy[J]. Endocrine,2012,42(3):700-707.
[12] Lecke SB, Morsch DM, Spritzer PM. CYP19 gene expression in subcutaneous adipose tissue is associated with blood pressure in women with polycystic ovary syndrome[J]. Steroids,2011,76(12):1383-1388.
[13] Coban N, Onat A, Guclu-Geyik F, et al. Sex- and obesity-specific association of aromatase(CYP19A1)gene variant with apolipoprotein B and hypertension[J]. Arch Med Res,2015,46(7):564-571.
[14] Wang B, Fu ZY, Huang D, et al. A novel polymorphism of the CYP19 gene is associated with essential hypertension in China[J]. J Am Coll Cardiol, 2015,66(16):1788-1790.
[15] Osterlund KL, Handa RJ, Gonzales RJ. Dihydrotestosterone alters cyclooxygenase-2 levels in human coronary artery smooth muscle cells[J]. Am J Physiol Endocrinol Metab,2010,298(4):E838-E845.
[16] Dowsett M, Folkerd E. Reduced progesterone levels explain the reduced risk of breast cancer in obese premenopausal women:a new hypothesis[J]. Breast Cancer Res Treat,2015,149(1):1-4.
[17] Brown KA. Impact of obesity on mammary gland inflammation and local estrogen production[J]. J Mammary Gland Biol Neoplasia,2014,19(2):183-189.
[18] de Groot PC, Dekkers OM, Romijn JA, et al. PCOS, coronary heart disease, stroke and the influence of obesity:a systematic review and meta-analysis[J]. Hum Reprod Update,2011,17(4):495-500.
[19] Saltiki K, Papageorgiou G, Voidonikola P, et al. Endogenous estrogen levels are associated with endothelial function in males independently of lipid levels[J]. Endocrine,2010,37(2):329-335.
[20] Jeon GH, Kim SH, Yun SC, et al. Association between serum estradiol level and coronary artery calcification in postmenopausal women[J].Menopause,2010,17(5):902-907.
[21] 郑红云,李艳,马楠等.性激素失平衡与男性冠心病发病的相关性研究[J].国际检验医学杂志,2014,35(1):12-13,16.
[22] Naessen T, Sjogren U, Bergquist J, et al. Endogenous steroids measured by high-specificity liquid chromatography-tandem mass spectrometry and prevalent cardiovascular disease in 70-year-old men and women[J]. J Clin Endocrinol Metab,2010,95(4):1889-1897.
[23] Dai W, Li Y, Zheng H. Estradiol/testosterone imbalance:impact on coronary heart disease risk factors in postmenopausal women[J]. Cardiology,2012,121(4):249-254.
[24] Beitelshees AL, Johnson JA, Hames ML, et al. Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner[J]. PLoS One,2010,5(12):e15180.
[25] Bampali K, Grassos C, Mouzarou A, et al. Genetic variant in the CYP19A1 gene associated with coronary artery disease[J]. Genet Res Int,2015,2015:820323.
[26] Wang B, Fu ZY, Ma YT, et al. Identification of a CYP19 gene single-nucleotide polymorphism associated with a reduced risk of coronary heart disease[J]. Genet Test Mol Biomarkers,2016,20(1):2-10.
[27] Arca M. Dyslipidemia and Cardiovascular Risk in Obesity[M]. Multidisciplinary Approach to Obesity, 2014:121-130.
[28] Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology[J]. Nature,2015,518(7538):197-206.
[29] Scott NJ, Cameron VA, Raudsepp S, et al. Generation and characterization of a mouse model of the metabolic syndrome:apolipoprotein E and aromatase double knockout mice[J]. Am J Physiol Endocrinol Metab,2012,302(5):E576-E584.
[30] Edwards TL,Velez Edwards DR, Villegas R, et al. HTR1B, ADIPOR1, PPARGC1A, and CYP19A1 and obesity in a cohort of Caucasians and African Americans:an evaluation of gene-environment interactions and candidate genes[J]. Am J Epidemiol,2012,175(1):11-21.
[31] de Sousa-e-Silva EP, Conde DM, Costa-Paiva L, et al. Cardiovascular risk in middle-aged breast cancer survivors:a comparison between two risk models[J]. Rev Bras Ginecol Obstet,2014,36(4):157-162.
[32] Rose DP, Gracheck PJ, Vona-Davis L. The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer[J]. Cancers,2015,7(4): 2147-2168.
相似文献/References:
[1]吴亚希,杨丽霞.Toll样受体4与心血管疾病的研究进展[J].心血管病学进展,2016,(1):58.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.015]
WU Yaxi,YANG Lixia.Research Progress of Relationship Between Toll-like Receptor 4 and
Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(4):58.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.015]
[2]汪汉,综述.显微镜下多血管炎的心血管病变[J].心血管病学进展,2016,(2):170.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.019]
WANG Han.Cardiovascular Involvement in Microscopic Polyangitis[J].Advances in Cardiovascular Diseases,2016,(4):170.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.019]
[3]汪汉,综述.几种少见的风湿性疾病的心血管表现[J].心血管病学进展,2016,(3):305.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.024]
WANG Han.Cardiovascular Manifestations in Rare Rheumatic Diseases[J].Advances in Cardiovascular Diseases,2016,(4):305.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.024]
[4]李子进,综述,李景东,等.锚蛋白B在心血管系统中作用的研究进展[J].心血管病学进展,2016,(4):341.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.004]
LI Zijin,LI Jingdong.Research Progress of Ankyrin-B in Cardiovascular System[J].Advances in Cardiovascular Diseases,2016,(4):341.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.004]
[5]万永伦,综述,高倩萍,等.红细胞分布宽度与心血管疾病之间的病理生理联系[J].心血管病学进展,2016,(4):387.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.016]
WAN Yonglun,GAO Qianping.Pathophysiological Connection Between Red Blood Distribution
Width and Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2016,(4):387.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.016]
[6]冉丹,佘强.载脂蛋白C-Ⅲ在心血管疾病中的研究进展[J].心血管病学进展,2015,(5):613.[doi:10.3969/j.issn.1004-3934.2015.05.023]
RAN Dan,SHE Qiang.Progress of Apolipoprotein C-Ⅲ in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2015,(4):613.[doi:10.3969/j.issn.1004-3934.2015.05.023]
[7]隆雪原,罗素新.睡眠与心血管疾病相互关系的研究进展[J].心血管病学进展,2015,(6):735.[doi:10.3969/j.issn.1004-3934.2015.06.020]
LONG Xueyuan,LUO Suxin.Research Progress of the Relationship Between Sleep and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2015,(4):735.[doi:10.3969/j.issn.1004-3934.2015.06.020]
[8]李涛 杨思姝 钱永军.纳米技术在心血管疾病中的最新应用[J].心血管病学进展,2019,(5):708.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.012]
LI Tao,YANG Sishu,QIAN Yongjun.Nanotechnology in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(4):708.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.012]
[9]潘乐 汪翔 龚惠.单细胞测序在心血管系统中的应用[J].心血管病学进展,2020,(12):1227.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.001]
PAN Le,WANG Xiang,GONG Hui.Application of single cell sequencing in cardiovascular system[J].Advances in Cardiovascular Diseases,2020,(4):1227.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.001]
[10]于洋杰 谢坤 高秀芳 施海明 李勇.非高密度脂蛋白胆固醇可以替代低密度脂蛋白胆固醇吗？[J].心血管病学进展,2021,(1):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
YU Yangjie,XIE Kun,GAO Xiufang,et al.Can LDL-C be Replaced by non-HDL-C[J].Advances in Cardiovascular Diseases,2021,(4):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]